COVID-19 vaccine updates from around the world — these nine candidates are at phase III trial stage

Clinical Stage: Phase IIIAstraZeneca-Oxford’s vaccine candidate — ChAdOx1 — is the most advanced COVID-19 candidate in the world. Clinical trials for the most-advanced coronavirus vaccine candidate developed by AstraZeneca and the University of Oxford were put on hold on September 6, over safety concerns. AstraZeneca has resumed trials in Brazil and the UK, but the late-stage trials will remain suspended in the US “for several days.” Despite the halt, the US-based pharma giant says its vaccine could be available this year or by early 2021. In India, Serum Institute too had to pause the trials, however, the Drugs Controller General of India today said it can resume human trials again. Clinical Stage: Phase IIIAmerican pharma major Pfizer is developing a potential coronavirus vaccine along with BioNTech.It is under Phase III trials right now. Pfizer’s potential COVID-19 vaccine is one of the three vaccines backed by the US government. The Trump government has already placed an initial order of 100 million doses for $1.95 billion. Pfizer has already manufactured “hundreds of thousands of doses” and might launch the vaccine shot by year-end, CEO Albert Bourla said. On September 18, Pfizer also revealed how they are running the trials. The US pharma giant believes its coronavirus vaccine is likely to show effectiveness “early” in the trials, reported Reuters. Clinical Stage: Phase IIICanSino was the first pharma company in the world to get a go-ahead for the military use of an experimental coronavirus vaccine candidate. It was also the first company to start a clinical trial back in March. Can Sino Biologics is developing the potential coronavirus based on Adenovirus known as Ad5. The vaccine is under Phase III trials right now. According to the Phase 1 and Phase 2 trial data released by The Lancet, CanSino’s COVID-19 vaccine is safe and can trigger an immune response in people. Chinese researchers claim the potential vaccine can protect people from “all the known mutations of the virus.”Clinical Stage: Phase IIIRussia’s potential COVID-19 vaccine, Sputnik V, is under Phase III trials. Gamaleya Research Institute — a part of Russia’s Health Ministry — is testing the virus on over 40,000 people. Several scientists across the world have been criticizing Russia over safety concerns. According to Russian health minister Mikhail Murashko, one in seven volunteers had side effects after they had a shot of Sputnik V. “Approximately 14% have small complaints of weakness, muscle pain for 24 hours and an occasional increase in body temperature,” reported Russian Agency TASS quoting Murashko. On September 8, the Russian government sought India’s help in manufacturing the Sputnik V vaccine and also to conduct Phase III trials in India. Clinical Stage: Phase IIIJohnson and Johnson’s Janssen unit is planning started phase III clinical trials of its coronavirus vaccine. It will recruit upto 60,000 volunteers in US, South Africa, Brazil, Argentina, Columbia and Chile. It further said that we would know whether the one-shot vaccine works by the end of 2020, Janssen Pharmaceuticals is among the many companies which have struck a deal with Britain. It has also struck a $1 billion deal with the US government for 100 million doses. J&J aims to supply more than one billion doses of COVID-19 vaccine globally through 2021. Clinical Stage: Phase IIIChinese pharmaceutical Sinovac Biotech on July 16 got the approval to conduct Phase III clinical trial for its coronavirus vaccine candidate, CoronaVac. It started developing the COVID-19 vaccine as early as January 28. It aims to introduce its coronavirus vaccine this year.Clinical Stage: Phase IIIChinese pharmaceutical, Sinpharm, is the first in the world to start Phase III trials on a potential coronavirus vaccine. The vaccine is being developed in Wuhan — the same place where coronavirus first originated. Sinopharm is working on an “inactivated” vaccine. These vaccines are developed after scientists grow the virus in a laboratory setting from scratch — in this case, SARS-CoV-2 — and then try to kill it. Clinical Stage: Phase IIISinopharm is developing another coronavirus vaccine with the Beijing Institute of Biological Products. The inactivated vaccine is said to be available in the market by December for $150, reported Russian News Agency TASS. The vaccine is under Phase III trials right now. The Beijing Institute of Biological Products claims that it can produce up to 120 mln inactivated vaccines a year. Clinical Stage: Phase IIIModerna is set to complete its Phase III trials by the end of September. It enrolled over 30,000 people in the US and started human trials. It aims to reveal the test results of the human trials by October and launch the vaccine by the end of the year. It is planning to manufacture 500 million doses of vaccine per year from 2021.

Cookies on the Business Insider India website

COVID-19 vaccine updates from around the world — these nine candidates are at phase III trial stage

The University of Oxford and AstraZeneca

2. BioNTech/Fosun Pharma/Pfizer

CanSino Biological Inc. and Beijing Institute of Biotechnology

Gamaleya Research Institute

Janssen Pharmaceutical Companies

Sinovac

Wuhan Institute of Biological Products/Sinopharm

Beijing Institute of Biological Products/Sinopharm

Moderna/NIAID

Cookies on the Business Insider India website

COVID-19 vaccine updates from around the world — these nine candidates are at phase III trial stage

The University of Oxford and AstraZeneca

​2. BioNTech/Fosun Pharma/Pfizer

​CanSino Biological Inc. and Beijing Institute of Biotechnology

​Gamaleya Research Institute

​Janssen Pharmaceutical Companies

​Sinovac

​Wuhan Institute of Biological Products/Sinopharm

​Beijing Institute of Biological Products/Sinopharm

​Moderna/NIAID

2. BioNTech/Fosun Pharma/Pfizer

CanSino Biological Inc. and Beijing Institute of Biotechnology

Gamaleya Research Institute

Janssen Pharmaceutical Companies

Sinovac

Wuhan Institute of Biological Products/Sinopharm

Beijing Institute of Biological Products/Sinopharm

Moderna/NIAID